Evidence map›Paper›PMID 41624004›Full record

ArticleFrontiers in immunology2026

Correction: Perspective: IL-15 cytokine-armored NK cells as ready-to-use immunotherapy for diverse malignancies: therapeutic potential and toxicity risks.

Scott L Baughan, Timothy Folsom, Matt Johnson, Joshua Kreuger, Beau R Webber, Branden S Moriarity

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Scott L BaughanDepartment of Medicine, University of Minnesota Twin Cities, Minneapolis, MN, United States.
Timothy FolsomCenter for Genome Engineering, University of Minnesota, Minneapolis, MN, United States.
Matt JohnsonCenter for Genome Engineering, University of Minnesota, Minneapolis, MN, United States.
Joshua KreugerCenter for Genome Engineering, University of Minnesota, Minneapolis, MN, United States.
Beau R WebberCenter for Genome Engineering, University of Minnesota, Minneapolis, MN, United States.
Branden S MoriarityCenter for Genome Engineering, University of Minnesota, Minneapolis, MN, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fimmu.2025.1704404.].

Indexed as

CAR-NK cellsCAR-T cell therapychimeric antigen receptors (CARs)cytokine release syndromecytokine release syndrome (CRS)IL-15 cytokine-armored CAR-NKnatural killer (NK) cells

Identifiers

PMID41624004
PMCPMC12853196

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.